Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCα and PKCθ

Journal of Virology

Volumn 79, Issue 15, 2005, Pages 9821-9830

  Trushin, Sergey A ^a   Bren, Gary D ^a   Asin, Susana ^b   Pennington, Kevin N ^b   Paya, Carlos V ^a,b   Badley, Andrew D ^a  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; ISOPROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER DERIVATIVE; PROSTATIN; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C ALPHA AGONIST; PROTEIN KINASE C THETA; PROTEIN KINASE C THETA AGONIST; RNA; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; ERADICATION THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RNA ANALYSIS; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; VIRUS LATENCY; VIRUS REACTIVATION;

CELLS, CULTURED; HIV-1; HUMANS; ISOENZYMES; JURKAT CELLS; PHORBOL ESTERS; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; RECEPTORS, ANTIGEN, T-CELL; VIRUS ACTIVATION; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 22544466722     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.15.9821-9830.2005     Document Type: Article

References (61)

1. Adams, M., L. Sharmeen, J. Kimpton, J. M. Romeo, J. V. Garcia, B. M. Peterlin, M. Groudine, and M. Emerman. 1994. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc. Natl. Acad. Sci. USA 91:3862-3866.
2. 2+ signaling by PKCθ in restimulated T cells via a Tec kinase-dependent pathway. Eur. J. Immunol. 34:2001-2011.
3. Baier, G., D. Telford, L. Giampa, K. M. Coggeshall, G. Baier-Bitterlich, N. Isakov, and A. Altman. 1993. Molecular cloning and characterization of PKC-theta, a novel member of the protein kinase C (PKC) gene family expressed predominantly in hematopoietic cells. J. Biol. Chem. 268:4997-5004.
4. Baier-Bitterlich, G., F. Uberall, B. Bauer, F. Fresser, H. Wachter, H. Grunicke, G. Utermann, A. Altman, and G. Baier. 1996. Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes. Mol. Cell. Biol. 16:1842-1850.
5. Bera, T. K., P. E. Kennedy, E. A. Berger, C. F. I. Barbas, and I. Pastan. 1998. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol. Med. 4:384-391.
6. Bi, K., Y. Tanaka, N. Coudronniere, K. Sugie, S. Hong, M. J. B. van Stipdonk, and A. Altman. 2001. Antigen-induced translocation of PKC-theta to membrane rafts is required for T cell activation. Nat. Immunol. 2:556-563.
7. Biancotto, A., J.-C. Grivel, F. Gondois-Rey, L. Bettendroffer, R. Vigne, S. Brown, L. B. Margolis, and I. Hirsch. 2004. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J. Virol. 78:10507-10515.
8. Bocklandt, S., P. M. Blumberg, and D. H. Hamer. 2003. Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. Antivir. Res. 59:89-98.
9. Brooks, D. G., P. A. Arlen, L. Gao, C. M. Kitchen, and J. A. Zack. 2003. Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc. Natl. Acad. Sci. USA 100:12955-12960.
10. Brooks, D. G., D. H. Hamer, P. A. Arlen, L. Gao, G. Bristol, C. M. R. Kitchen, E. A. Berger, and J. A. Zack. 2003. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19:413-423.
11. Brooks, D. G., S. G. Kitchen, C. M. R. Kitchen, D. D. Scripture-Adams, and J. A. Zack. 2001. Generation of HIV latency during thymopoiesis. Nat. Med. 7:459-464.
12. Chapuis, A. G., G. Paolo Rizzardi, C. D'Agostino, A. Attinger, C. Knabenhans, S. Fleury, H. Acha-Orbea, and G. Pantaleo. 2000. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat. Med. 6:762-768.
13. Chun, T.-W., L. M. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, T. C. Quinn, Y.-H. Kuo, R. Brookmeyer, M. A. Zeiger, P. Barditch-Croveo, and R. F. Siliciano. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
14. Chun, T.-W., D. Finzi, J. Margolick, K. Chadwick, D. Schwartz, and R. F. Siliciano. 1995. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1:1284-1290.
15. Chun, T.-W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. M. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A, S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
16. Coudronniere, N., M. Villalba, N. Englund, and A. Altman. 2000, NF-κB activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta. Proc. Natl. Acad. Sci. USA 97:3394-3399.
17. Duh, E. J., W. J. Maury, T. M. Folks, A. S. Fauci, and A. B. Rabson. 1989. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat. Proc. Natl. Acad. Sci. USA 86:5974-5978,
18. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
19. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
20. Folks, T. M., K. A. Clouse, J. Justement, A. Rabson, E. Duh, J. H. Kehrl, and A. S. Fauci. 1989. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl. Acad. Sci. USA 86:2365-2368.
21. Goldstein, H., M. Pettoello-Mantovani, T. K. Bera, I. H. Pastan, and E. A. Berger. 2000. Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice. J. Infect. Dis. 181:921-926,
22. Gulakowski, R. J., J. B. McMahon, R. W. Buckheit, Jr., K. R. Gustafson, and M. R. Boyd. 1997. Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antivir. Res. 33:87-97.
23. Gustafson, K. R., J. H. Cardellina, J. B. McMahon, R. J. Gulakowski, J. Ishitoya, Z. Szallasi, N. E. Lewin, P. M. Blumberg, O. S. Weislow, J. A. Beutler, R. W. Buckheit, Jr., G. M. Cragg, P. A. Cox, J. P. Bader, and M. R. Boyd. 1992. A nonpromoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J. Med. Chem. 35:1978-1986.
24. Hamer, D. H., S. Bocklandt, L. McHugh, T. W. Chun, P. M. Blumberg, D. M. Sigano, and V. E. Marquez. 2003. Rational design of drugs that induce human immunodeficiency virus replication. J. Virol. 77:10227-10236.
25. Han, X. M., A. Laras, M. P. Rounseville, A. Kumar, and P. R. Shank. 1992. Human immunodeficiency virus type 1 Tat-mediated trans activation correlates with the phosphorylation state of a cellular TAR RNA stem-binding factor. J. Virol. 66:4065-4072.
26. Havlir, D. V., P. B. Gilbert, K. Bennett, A. C. Collier, M. S. Hirsch, P. Tebas, E. M. Adams, L. J. Wheat, D. Goodwin, S. Schnittman, M. K. Holohan, and D. D. Richman. 2001. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 15:1379-1388.
27. Jakobovits, A., A. Rosenthal, and D. J. Capon. 1990. Trans-activation of HIV-1 LTR-directed gene expression by tat requires protein kinase C. EMBO J. 9:1165-1170.
28. Jones, K. A., and B. M. Peterlin. 1994. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:717-743.
29. Kinter, A. L., G. Poli, W. Maury, T. M. Folks, and A. S. Fauci. 1990. Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J. Virol. 64:4306-4312.
30. Korin, Y. D., D. G. Brooks, S. Brown, A. Korotzer, and J. A. Zack. 2002. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 76:8118-8123.
31. Kulkosky, J., D. M. Culnan, J. Roman, G. Dornadula, M. Schnell, M. R. Boyd, and R. J. Pomerantz. 2001. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98:3006-3015.
32. Kulkosky, J., G. Nunnari, M. Otero, S. Calarota, G. Dornadula, H. Zhang, A. Malin, J. Sullivan, Y. Xu, J. DeSimone, T. Babinchak, J. Stern, W. Cavert, A. Haase, and R. J. Pomerantz. 2002. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186:1403-1411.
33. Kulkosky, J., J. Sullivan, Y. Xu, E. Souder, D. H. Hamer, and R. J. Pomerantz. 2004. Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Res. Hum. Retrovir. 20:497-505.
34. Li, Y., J. Hu, R. Vita, B. Sun, H. Tabata, and A. Altman. 2004. SPAK kinase is a substrate and target of PKC-theta in T-cell receptor-induced AP-1 activation pathway. EMBO J. 23:1112-1122.
35. Li, Y., G. Mak, and B. R. Franza, Jr. 1994. In vitro study of functional involvement of Sp1, NF-κB/Rel, and AP1 in phorbol 12-myristate 13-acetate-mediated HIV-1 long terminal repeat activation. J. Biol. Chem. 269:30616-30619.
36. Lin, X., A. O'Mahony, Y. Mu, R. Geleziunas, and W. C. Greene. 2000. Protein kinase C-theta participates in NF-κB activation induced by CD3-CD28 costimulation through selective activation of IκB kinase β. Mol. Cell. Biol. 20:2933-2940.
37. Lori, F., A. Malykh, A. Cara, D. Sun, J. N. Weinstein, J. Lisziewicz, and R. C. Gallo. 1994. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266:801-805.
38. McHugh, L., S. Hu, B. K. Lee, K. Santora, P. E. Kennedy, E. A. Berger, I. Pastan, and D. H. Hamer. 2002. Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis. J. Biol. Chem. 277:34383-34890.
39. Michie, A. M., and R. Nakagawa. 2005. The link between PKCα regulation and cellular transformation. Immunol. Lett. 96:155-162.
40. Nabel, G., and D. Baltimore. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711-713.
41. Osborn, L., S, Kunkel, and G. J. Nabel. 1989. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl. Acad. Sci. USA 86:2336-2340.
42. 2+ mobilization after CD3 stimulation. J. Immunol. 147:3145-3148.
43. 2+ mobilization and NFAT cell activation in primary mouse T cells. J. Exp. Med. 197:1525-1535.
44. Prins, J. M., S. Jurriaans, R. M. E. van Praag, H. Blaak, R. van Rij, P. Schellekens, I. J. M. ten Berge, S.-L. Yong, C. H. Fox, M. T. L. Roos, F. de Wolf, J. Goudsmit, H. Schuitemaker, and J. M. A. Lange. 1999. Immunoactivation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13:2405-2410.
45. Qatsha, K A., C. Rudolph, D. Marme, C. Schachtele, and W. S. May. 1993. Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc. Natl. Acad. Sci. USA 90:4674-4678.
46. Roebuck, K. A., D. S. Gu, and M. F. Kagnoff. 1996. Activating protein-1 cooperates with phorbol ester activation signals to increase HIV-1 expression. AIDS 10:819-826.
47. Ron, D., E. W. Napolitano, A. Voronova, N. J. Vasquez, D. N. Roberts, B. L. Calio, R. H. Caothien, S. M. Pettiford, S. Wellik, J. B. Mandac, and L. M. Kauvar. 1999. Direct interaction in T-cells between PKCθ and the tyrosine kinase p59fyn. J. Biol. Chem. 274:19003-19010.
48. Rullas, J., M. Bermejo, J. Garcia-Perez, M. Beltran, N. Gonzalez, M. Hezareh, S. J. Brown, and J. Alcami. 2004. Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antivir. Ther. 9:545-554.
49. Scripture-Adams, D. D., D. G. Brooks, Y. D. Korin, and J. A. Zack. 2002. Interleukin-7 induced expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J. Virol. 76:13077-13082.
50. + T cells. Nat. Med. 9:727-728.
51. Sun, Z., C. W. Arendt, W. Ellmeier, E. M. Schaeffer, M. J. Sunshine, L. Gandhi, J. Annes, D. Petrizilka, A. Kupfer, P. L. Schwartzberg, and D. R. Littman. 2000. PKC-theta is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes. Nature 404:402-407.
52. Thebault, S., and J. Ochoa-Garay. 2004. Characterization of TCR-induced phosphorylation of PKCθ in primary murine lymphocytes. Mol. Immunol. 40:931-942.
53. Trushin, S. A., K. N. Pennington, A. Algeciras-Schimnich, and C. V. Paya. 1999. Protein kinase C and calcineurin synergize to activate IκB kinase and NF-κB in T lymphocytes. J. Biol. Chem. 274:22923-22931.
54. Trushin, S. A., K. N. Pennington, E. M. Carmona, S. Asin, D. N. Savoy, D. D. Billadeau, and C. V. Paya. 2003. Protein kinase C-α (PKC-α) acts upstream of PKC-theta to activate IκB kinase and NF-κB in T lymphocytes. Mol. Cell. Biol. 23:7068-7081.
55. + T cell depletion. J. Clin. Immunol. 21:218-226.
56. Werlen, G., E. Jacinto, Y. Xia, and M. Karin. 1998. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. EMBO J. 17:3101-3111.
57. Williams, S. A., L. F. Chen, H. Kwon, D. Fenard, D. Bisgrove, E. Verdin, and W. C. Greene. 2004. Prostratin antagonizes HIV latency by activating NF-κB. J. Biol. Chem. 279:42008-42017.
58. Wong, J. K., M. Hezareh, H. F. Gunthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
59. Yang, B., L. Gao, L. Li, Z. Lu, X. Fan, C. A. Patel, R. J. Pomerantz, G. C. DuBois, and H. Zhang. 2003. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem. 278:6596-6602.
60. Yang, X., Y. Chen, and D. Gabuzda. 1999. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-κB. J. Biol. Chem. 274:27981-27988.
61. Zhang, L., C. Chung, B.-S. Hu, T. He, Y. Guo, A. J. Kim, E. Sklusky, X. Jin, A. Hurley, B. Ramratnam, M. Markowitz, and D. D. Ho. 2000. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J. Clin. Investig. 106:839-845.